Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
10-K - BioNexus Gene Lab Corp (0001737523) (Filer)
NT 10-K - BioNexus Gene Lab Corp (0001737523) (Filer)
8-K - BioNexus Gene Lab Corp (0001737523) (Filer)
KUALA LUMPUR, Malaysia, March 11, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) today announced that, in connection with its Fidelion Diagnostics Pte. Ltd ("Fidelion") transaction, Dr. Muthu Meyyappan has been appointed Chief Commercial Officer of Fidelion. Fidelion is a precision diagnostics company focused on advancing next-generation oncology testing technologies, including minimal residual disease (MRD) liquid biopsy assays. Fidelion serves as the international intellectual property and commercialization vehicle for the VitaGuard™ MRD technology developed by Tongshu Gene, supporting commercialization initiatives outside Greater China. BGLC is a strategic investor in Fi
Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BioNexus" or the "Company"), today announced the completion of a governance restructuring of its wholly owned subsidiary, Chemrex Corporation Sdn. Bhd. ("Chemrex"). As part of this restructuring, Chemrex's board has been streamlined to two directors: Matthew L. Barsing, ChairmanAngeline Chong, Chief Financial Officer of BioNexus, Director New officers are expected to be appointed in the coming months. Chemrex remains a wholly owned private subsidiary of BioNexus and operates un
KUALA LUMPUR, Malaysia, Jan. 28, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BioNexus" or the "Company"), a technology-driven precision diagnostics company, today announced the formal commencement of its 2026 Deployment Phase for the VitaGuard™ Minimal Residual Disease (MRD) platform. This phase marks the transition of VitaGuard™ from a technological breakthrough into what the Company believes will be a scalable oncology infrastructure, designed to displace high-cost legacy monitoring systems throughout Southeast Asia. Initial deployments are expected to commence in select Southeast Asian medical hubs during 2026. The Economic Imperative: Shattering the $3,000 Barrier
3 - BioNexus Gene Lab Corp (0001737523) (Issuer)
3 - BioNexus Gene Lab Corp (0001737523) (Issuer)
3 - BioNexus Gene Lab Corp (0001737523) (Issuer)
Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BioNexus" or the "Company"), today announced the completion of a governance restructuring of its wholly owned subsidiary, Chemrex Corporation Sdn. Bhd. ("Chemrex"). As part of this restructuring, Chemrex's board has been streamlined to two directors: Matthew L. Barsing, ChairmanAngeline Chong, Chief Financial Officer of BioNexus, Director New officers are expected to be appointed in the coming months. Chemrex remains a wholly owned private subsidiary of BioNexus and operates un
KUALA LUMPUR, Malaysia, April 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC), a biotechnology company specializing in precision diagnostics and specialty chemical solutions, today announced that it has received official notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming the Company has regained full compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. This important milestone reaffirms the Company's standing as a compliant and growth-focused public company. It marks the successful conclusion of a focused compliance initiative and paves the way for the Company to pursue its bold innovation roadmap, capit
SC 13G - BioNexus Gene Lab Corp (0001737523) (Subject)